What does primrose mrna — gross carrying value mean?

Represents the total original cost or acquisition value of financial royalty assets associated with the mRNA technology segment before any adjustments for impairment or allowances. This metric reflects the initial capital investment or valuation assigned to the royalty rights within this specific product category. It serves as a baseline for assessing the total asset exposure within the mRNA portfolio.

Ligand Pharmaceuticals LGND Primrose mRNA — Gross carrying value

Other product segments

Qarziba

$103.72M—

Similar metrics at other companies

AMEGross Carrying Amount

$5.13B+9.4%

SIRIPandora and Off-platform — Gross Carrying Value

$442M0.0%

TEXMP — Goodwill, Gross

$214M-1.4%

WMBGross Carrying Amount

$10.51B0.0%

GNTXOther — Gross carrying value

$38.4M—

MSCIGross Carrying Amount

$2.1B+6.6%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's primrose mrna — gross carrying value.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's primrose mrna — gross carrying value?: Ligand Pharmaceuticals (LGND) reported primrose mrna — gross carrying value of $3.28M in Q1 2026.
What does primrose mrna — gross carrying value mean?: Represents the total original cost or acquisition value of financial royalty assets associated with the mRNA technology segment before any adjustments for impairment or allowances. This metric reflects the initial capital investment or valuation assigned to the royalty rights within this specific product category. It serves as a baseline for assessing the total asset exposure within the mRNA portfolio.